Singapore’s Aslan Pharma Gets Buy Rating from Jefferies

ASLN’s ‘004 is a fast follower, targeting an understood, de-risked path in atopic dermatitis [eczema],’ said Jefferies analyst Maury Raycroft.
( read original story …)


Search your Hotel